Quest Diagnostics had its Relative Strength (RS) Rating upgraded from 66 to 76 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Quest Diagnostics can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Quest Diagnostics is building a cup without handle with a 165.32 buy point. See if the stock can break out in heavy trade.
In terms of top and bottom line numbers, Quest Diagnostics has posted two quarters of increasing earnings growth. Revenue gains have also risen during the same period. The company is expected to release its next quarterly numbers on or around Jan. 30.
The company earns the No. 8 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Option Care Health and Guardant Health are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
